Egalet Corp., of Wayne, Pa., said it completed an end-of-phase II meeting with the FDA regarding Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.